Two genes, rif15 and rif16, of the rifamycin biosynthetic gene cluster in Amycolatopsis mediterranei likely encode a transketolase and a P450 monooxygenase, respectively, both essential for the conversion of rifamycin SV into B Amycolatopsis mediterranei produces an important antibiotic rifamycin, the biosynthesis of which involves many unusual modifications. Previous work suggested a putative P450 enzyme encoded by rif16 within the rifamycin biosynthetic gene cluster (rif ) was required for the conversion of the intermediate rifamycin SV into the end product rifamycin B. In this study, we genetically proved that a putative transketolase encoded by rif15 is another essential enzyme for this conversion. Expression of merely rif15 and rif16 in a rif cluster null mutant of A. mediterranei U32 was able to convert rifamycin SV into B. However, this Rif15-and Rif16-mediated conversion was only detected in intact cells of A. meidterranei, but not in Streptomyce coelicolor or Mycobacterium smegmatis, suggesting that yet-characterized gene(s) in A. mediterranei other than those encoded by the rif cluster should be involved in this process.
Introduction
A rare actinomycete, Amycolatopsis mediterranei, is known to produce the commercially important antibiotic rifamycins, derivatives of which are particularly effective against the pathogenic mycobacteria i.e. Mycobacterium tuberculosis and Mycobacterium leprae [1] . After decades of extensive rifamycin treatment, tuberculosis remains a serious threat to human health due to the increasing emergence of rifamycin-resistant M. tuberculosis clinical isolates [2] . Although a large number of semi-synthetic rifamycin derivatives have been prepared since its discovery, the structural modifications of derivatives are limited primarily at the C-3 or C-4 positions of the aromatic core unit, majorly due to the complexity of the molecule [1] . Although alternative methodologies, such as combinatorial biosynthesis and mutasynthesis, were suggested to develop more lead compounds with structural diversity [3] [4] [5] , thorough delineation of the biosynthetic process, particularly the unusual modifications onto the core moiety, is required to achieve the goal.
The rifamycin biosynthetic pathway was studied extensively by both classical feeding and mutagenesis experiments and by means of both molecular genetics and biochemistry [5] [6] [7] [8] [9] [10] [11] . The nearly 90-kb rifamycin biosynthetic gene clusters (rif ) from a rifamycin B producer, A. mediterranei S699 [7] , and a rifamycin SV-producing strain, A. mediterranei U32, were highly similar [12] . Comparative analyses among the rif clusters from A. mediterranei [7, 12] and Salinispora arenicola [13, 14] suggested that the A. mediterranei rif cluster probably include the open reading frames (ORFs) from rifS (AMED_0613 for the U32 genome) to rif36 (AMED_0655 for the U32 genome, or rif-orf36 designated for S699) [ Fig. 1(A) ]. The 3-amino-5-hydroxybenzoic acid (AHBA) is the starter unit and two molecules of malonyl-CoA and eight molecules of (S)-methylmalonyl-CoA are known to be extender units to form the initial macrocyclic intermediate proansamycin X [1, 7] . Several tailoring reactions, such as hydroxylation, acetylation, and methylation, are required to form the late intermediate rifamycin SV [5, 10, 11] . However, the last step, which converts rifamycin SV into the end product rifamycin B, was not determined [1, 5] until we identified a putative P450 enzyme encoded by rif16 was required for this conversion [12] . In this study, we reinvestigated this essential role of Rif16 in a rifamycin B-producing strain A. mediterranei ATCC 21789 and identified a putative transketolase encoded by rif15 as another essential enzyme required for this conversion. Moreover, expression of merely Rif15 and Rif16 was shown to be sufficient for the conversion of rifamycin SV into B in a rif cluster null mutant of A. mediterranei U32. However, yet-characterized gene(s) in A. mediterranei other than those encoded by the rif cluster was thought to be involved in this conversion because Rif15 and Rif16 failed to convert rifamycin SV into B when they were heterologously expressed in either Streptomyce coelicolor or Mycobacterium smegmatis. These results will pave the solid stage for further exploration of novel molecular mechanisms catalyzed by this newly identified pair of transketolase and P450.
Materials and Methods
Bacterial strains, plasmids, primers, and media Bacterial strains and plasmids, and primers used in this study were listed in Tables 1 and 2 , respectively. Escherichia coli DH5a was used for plasmid DNA construction. E. coli ET12567/pUZ8002 was used for E. coli-Streptomyces conjugation [15] . A. mediterranei was grown in Benett medium [12] . S. coelicolor M145 was grown in Tryptone soya broth or yeast extract-malt extract media [15] . Rifamycin-resistant M. smegmatis B1D8 was grown in 5% glycerol-containing Luria-Bertani or Middlebrook 7H9 with 0.1% Tween and Dubos oleic albumin complex enrichment media [19] . Antibiotics were used as follows: ampicillin (100 mg/ml), apramycin (50 mg/ml), kanamycin (50 mg/ml), erythromycin (200 mg/ ml), and nalidixic acid (25 mg/ml).
Construction of rif gene null mutants in A. mediterranei ATCC 21789 and U32 The upstream and downstream homologous recombination DNA arms were cloned into the corresponding restriction sites of the pBluescript II KS (þ). In detail, the primers used for these cloning were: rif16KO11, rif16KO12, rif16KO21, and rif16KO22 for the disruption of ATCC 21789 rif16; rif15KO11, rif15KO12, rif15KO21, and rif15KO22 for the disruption of ATCC 21789 rif15A and B; rifKO11, rifKO12, rifKO21, and rifKO22 for the disruption of the whole rif cluster of U32 AMED_0612-AMED_0655; PrifKO11, PrifKO12, rifKO21, and rifKO22 for the disruption of U32 AMED_0633-AMED_0655; 11rifKO11, 11rifKO12, rifKO21, and rifKO22 for the disruption of U32 Figure 1 Schematic illustration of the rifamycin biosynthetic gene cluster (rif ) in A. mediterranei U32 (A) and a proposed pathway for the conversion of rifamycin SV into B (B) The rif cluster probably includes the open reading frames (ORFs) from AMED_0613 (rifS) to AMED_0655 (rif36, redesignated based on rif-orf36 for S699. This redesignated gene nomenclature was applied to all the other genes similarly named for S699.) [1] . In panel (B), the two carbon units added to rifamycin SV to form rifamycin B is indicated in red. This study Continued AMED_0643-AMED_0655. Next, the apramycin resistance gene fragment from pBCAm [16] was inserted into the designed EcoRV site located near the middle of the two homologous recombination arms. After sequencing verification, these recombinant plasmids were individually heat denatured and introduced into the competent cells of A. mediterranei by electroporation as described [17] . The desired double-homologous recombinant clones were selected for apramycin resistance and further confirmed by polymerase chain reaction (PCR) analysis with corresponding primers: 16KOveryfy1 and 16KOveryfy2 for ATCC 21789 rif16 mutant (GP4024); 15KOveryfy1 and 15KOveryfy2 for ATCC 21789 rif15 mutant (GP4025); two pairs of primers, rifKOveryfy1 and rifKOveryfy2, rifKOveryfy3 and rifKOveryfy4 for U32
AMED_0612-AMED_0655 mutant (GP4026); two pairs of primers, PrifKOveryfy1 and aprback, aprforth and rifKOveryfy4 for U32 AMED_0633-AMED_0655 mutant (GP4027); two pairs of primers, 11rifKOveryfy1 and aprback, aprforth and rifKOveryfy4 for U32 AMED_0643-AMED_0655 mutant (GP4028). The primers 16KOveryfy1 and 16KOveryfy2, 15KOveryfy1 and 15KOveryfy2 were derived from the genes rif16, and rif15A and B, respectively, and were located within the homologous recombination arms. The primers rifKOveryfy1, PrifKOveryfy1, 11rifKOveryfy1, and rifKOveryfy4 were located outside the homologous recombination arms, and the primers rifKOveryfy2, rifKOveryfy3, aprback, and aprforth were located within the apramycin resistance gene. Complementation of the A. mediterranei gene mutants For rif16 mutant, the complementation experiment was performed using plasmid pGP10169 as previously described [12] . For rif15 is probably controlled by the shared promoter for rif-orf14, about 300-bp Saccharopolyspora erythraea ermE promoter region using primers ermEP1 and ermEP2 was fused with the two ORFs rif15A and B with primers Ep15F and Ep15R by the designed restriction sites to construct a fused gene Ep-rif15. For rif16 and rif15A and B coexpression, the construction method was the same as for complementation of rif15 mutant except Ep15R being changed by Ep16R to obtain the gene fragment rif16-Ep-rif15. These gene fragments were first cloned into pBluescript II KS (þ) for sequencing and then ligated into the A. mediterranei multicopy plasmid pDXM4 to construct pGP10170 for Ep-rif15 and pGP10171 for rif16-Ep-rif15 used for electroporation of A. mediterranei. Heterologous expression of rif16 and rif15 For introduction of genes into S. coelicolor M145, the rif16-Ep-rif15 DNA fragment was first cloned into pSET152 to construct pGP10172 and then conjugated into M145 as described [15] . For M. smegmatis B1D8, the rif16-Ep-rif15 DNA fragment was first cloned into pMV306kan [18] to construct pGP10173 and then introduced into M. smegmatis by electroporation [19] .
In vivo conversion of chemically complemented rifamycin SV into B After the mycelium from the agar plates was cultured in liquid medium 1-2 days, standard rifamycin SV dissolved in ethanol was fed into the culture (40-80 mg/ml at final concentrations) and continued the growth for another 2-7 days for rifamycin constitution analysis by HPLC-MS, as described [12] .
Expression of rif15 and rif16 in E. coli BL21(DE3) rif15A and B were cloned as bicistronic into the NdeI and XhoI sites of pET-22b(þ) plasmid using primers Rf15PCR1 and Rf15PCR2, and rif16 was cloned into the NdeI and XhoI sites of pET-28b(þ) using primers Rf16PCR1 and Rf16PCR2. These plasmids were introduced into E. coli BL21(DE3) for expressing rif15A, rif15B, and rif16, respectively. For rif16 expression, 1 mM 5-aminolevulinic acid and 0.5 mM FeCl 3 were also fed into the culture when 1 mM isopropy-b-D-thiogalactoside was added for the induction.
In vitro assay for the conversion of rifamycin SV into B After the mycelium from the agar plate of the A. mediterranei U32 rifA mutant LYZL11 transformed with pGP10169 was grown in the Benett liquid medium for 2 days, the culture was 10% transferred into fresh Benett liquid medium for another 34 h and 51 h growth to be harvested for obtaining the cell crude extracts by ultrasonication. The in vitro assay mixture includes the 34 h or 51 h LYZL11( pGP10169) crude extracts, the cell crude extracts of E. coli BL21(DE3) expressing rif15A and rif15B, partially purified Rif16 proteins by nickle affinity chromatography, the Rif15 cofactor thiamine pyrophosphate (TPP), CaCl 2 , D-fructose-6-phosphate, and standard rifamycin SV.
Results and Discussion
Both Rif16 and Rif15 are involved in the conversion of rifamycin SV into B Previous studies [12] showed that the prototype Rif16 from the rifamycin B-producing strain A. mediterranei ATCC 21789 was a putative cytochrome P450 enzyme and able to complement for the defective Rif16 with an R84W mutation in the rifamycin SV-producing strain U32. To further verify the essential role of Rif16 in the biosynthesis of rifamycin B, we constructed a rif16 null mutant in strain ATCC 21789 (GP4024) as described in Materials and Methods. As expected, the culture of GP4024 did not produce any rifamycin B, but instead accumulated significant amount of rifamycin SV and its oxidized form, rifamycin S (Fig. 2, trace A) . Complementation of GP4024 with the prototype rif16 containing multicopy plasmid pGP10169 restored the rifamycin B production (Fig. 2, trace C) . As a negative control, the transformant with the vector alone produced a profile of rifamycins similar to that of GP4024 (Fig. 2, trace B) . Thus, the prototype Rif16, a putative P450, was confirmed to be involved in the process of converting rifamycin SV into B. Because the prototype Rif16 sequence is well conserved with other cytochrome P450 enzymes, well known for their monooxygenation functions [20, 21] , we searched in the rif cluster for possible suppliers of the two-carbon unit, glycolate, which should be essential for the synthesis of rifamycin B from rifamycin SV [ Fig. 1(B) ]. Previous studies showed that the conversion of rifamycin SV into B is a TPP-dependent process [8] , and thus, a putative TPP-dependent transketolase encoded by rif15A and rif15B (AMED_0651 and AMED_0652 designated for U32, or rif-orf15A and rif-orf15B designated for S699) was recognized as a candidate for further experimental verification. Both rif15A and rif15B in ATCC 21789 were knocked out via double-crossover homologous recombination to obtain the 4(rif15AB) null mutant-designated GP4025. As expected, GP4025 lost the ability to produce rifamycin B but accumulated rifamycin SV and S instead (Fig. 2, trace D) . When rif15A and rif15B, under the control of the ermE promoter from S. erythraea, were introduced back into GP4025, the production of rifamycin B was restored in the complement strain (Fig. 2, trace E) , while no production of rifamycin B was observed in the transformant with the control vector (data not shown). Taken together, the above experiments clearly showed that Rif15 was another necessary enzyme required for the conversion of rifamycin SV into B.
It was recently reported that, in another rifamycinproducing marine actinomycete, S. arenicola, this dedicated transketolase (encoded by Sare_1272 and Sare_1273) was required for AHBA formation [14] . However, the transketolase TktA from E. coli was known to be able to catalyze the conversion of 3-amino-3-deoxy-D-fructose-6-phosphate to imino-erythrose-4-phosphate during the biosynthesis of AHBA [22] and S. coelicolor transformed with rifG-N and rifJ genes was able to produce significant amount of AHBA [23] . Both data suggested that the transketolase function required for AHBA biosynthesis can be well complemented by a housekeeping enzyme. Therefore, it is reasonable to conclude, based on our genetic analysis, that Rif15 is involved in the conversion of rifamycin SV into B.
Among all the rif cluster genes, rif15 and rif16 are the only two required for the conversion of rifamycin SV into B Three rif cluster-related deletion mutants were systematically constructed in A. mediterranei U32: the whole rif cluster (AMED_0612-AMED_0655) deleted GP4026, the rifP to rif36 (AMED_0633-AMED_0655) deleted GP4027, and the rif11 to rif36 (AMED_0643-AMED_0655) deleted GP4028. All of them lost the ability to synthesize any rifamycins in their culture (data not shown). The wild-type rif16 of A. mediterranei ATCC 21789 with its own promoter region together with rif15A and rif15B controlled by the S. erythraea ermE promoter were cloned into the multicopy plasmid pDXM4 to obtain pGP10171. The plasmid was able to restore the ability of producing rifamycin B in the ATCC 21789 rif16 and rif15 null mutants (GP4024 and GP4025), respectively (data not shown), and was thus transformed into the mutants of GP4026, GP4027, and GP4028 individually. All the transformants harboring plasmid pGP10171, but not the transformants harboring the control plasmid pDXM4, produced rifamycin B when rifamycin SV was fed in the culture, and the representative results for GP4026/pGP10171 were shown in Fig. 3 , and the conversion efficiency was apparently culturing timedependent (Fig. 3) . These results clearly demonstrated that within the rif cluster, rif15 and rif16 were the only two genes of the rif cluster required for the conversion of rifamycin SV into B in A. mediterranei.
Our in vitro assays employing the crude cell extract of a U32 rifA mutant LYZL11 transformed with the ATCC 21789 rif16 (pGP10169) with or without the crude extracts of E. coli expressing Rif15 ( pGP10174) and Rif16 ( pGP10175) did not demonstrate any conversion of rifamycin SV into B (data not shown). This is, however, consistent with what Ghisalba et al. [8] once reported that they failed to demonstrate the conversion of rifamycin SV into B in any of their in vitro assays employing either permeabilized mycelium of A. mediterranei, crude protein extracts, cell fragments, or protoplasts. Thus, they proposed that the conversion system might be a membrane-associated labile multienzyme complex which only operates in intact cells. Further more, heterologous expression of rif16 and rif15 in S. coelicolor M145 ( pGP10172) and the rifamycinresistant M. smegmatis B1D8 ( pGP10173) (Materials and Methods) did not convert any rifamycin SV fed in the culture into B, although their expression could be readily detected by reverse transcriptase-PCR analysis (data not shown). This result inferred that certain yet-characterized gene(s) specific in A. mediterranei but other than those encoded by the rif cluster might be required for the conversion.
Based on the above experimental results and previous isotope-labeled precursor feeding studies [8] , a conversion process for rifamycin SV to B can be proposed [ Fig. 1(B) ] with the two-carbon donor unit supplied by the transketolase Rif15 followed by a monooxygenation step catalyzed by the P450 Rif16 as their conventional functions previously defined [20, 24] . However, further studies are required to test and to complete the gaps (e.g. the substrate of the transketolase) of the hypothesis, which might reveal Figure 2 Base peak chromatograms profiling the rifamycin products from fermentation cultures of rif15 or rif16 mutated A. mediterranei ATCC 21789 The experimental process is described in Materials and Methods. Sample traces from top to bottom are A. mediterranei ATCC 21789 rif16 mutant GP4024 (trace A), GP4024/pDXM4 (trace B), GP4024/pGP10169 (trace C), ATCC 21789 rif15 mutant GP4025 (trace D), and GP4025/ pGP10170 (trace E), respectively. The retention time for rifamycin B (RfB), SV (RfSV) and S (RfS) is around 7.5, 9, and 14.5 min, respectively. a novel chemistry catalyzed by these two or even with some additional enzyme(s). Figure 3 Base peak chromatograms profiling the rifamycin derivatives from the in vivo conversion of the in vitro supplied rifamycin SV standard chemical into B The experimental process is described in Materials and Methods. Sample traces from top to bottom, respectively, presented the GP4026/pGP10171 fermentation products collected at 54 h (trace A), 78 h (trace B), 102 h (trace C) and 174 h (trace D), and the GP4026/pDXM4 fermentation product collected at 174 h (trace E), after standard rifamycin SV was fed into the culture. The retention time for rifamycin B (RfB), SV (RfSV) and S (RfS) is around 7.5, 9, and 14.5 min, respectively.
